Authors: Julian Borchardt
In this short note, we show how to quickly verify the correctness of the estimates of the PML risk on natalizumab established in [Borchardt 2015]. Our approach is simple and elementary in that it requires virtually no knowledge of either statistics or probability theory. For a Kaplan-Meier curve of the PML incidence may be found in [O'Connor et al 2014], based on postmarketing data as of early August 2013, and just using the information from that chart, it is possible to directly derive estimates of the risk of PML in JCV-seropositive natalizumab-treated patients according to prior or no prior immunosuppression. Actually, the resulting figures are almost identical to the ones in [Borchardt 2015], even though the latter were obtained in a very different fashion.
Comments: 7 Pages. The results from this paper have been published in Multiple Sclerosis and Related Disorders (Vol. 8, pp. 145-150, 2016, doi:10.1016/j.msard.2016.03.005). The complete PDF can be downloaded for free from http://authors.elsevier.com/a/1TQWn7skoepyJK
Unique-IP document downloads: 434 times
Vixra.org is a pre-print repository rather than a journal. Articles hosted may not yet have been verified by peer-review and should be treated as preliminary. In particular, anything that appears to include financial or legal advice or proposed medical treatments should be treated with due caution. Vixra.org will not be responsible for any consequences of actions that result from any form of use of any documents on this website.
Add your own feedback and questions here:
You are equally welcome to be positive or negative about any paper but please be polite. If you are being critical you must mention at least one specific error, otherwise your comment will be deleted as unhelpful.